Overview

FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
Drugs used in chemotherapy such as FR901228 use different ways to stop cancer cells from dividing so they stop growing or die. Phase II trial to study the effectiveness of FR901228 in treating patients who have relapsed or refractory multiple myeloma
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Romidepsin